|
gptkbp:instanceOf
|
gptkb:antibiotic
|
|
gptkbp:affiliatedWith
|
gptkb:World_Health_Organization's_List_of_Essential_Medicines
|
|
gptkbp:approvedInUS
|
1991
|
|
gptkbp:ATCCode
|
gptkb:J01FA10
|
|
gptkbp:bioavailability
|
37% (oral)
|
|
gptkbp:brand
|
gptkb:Zithromax
gptkb:Zmax
|
|
gptkbp:CASNumber
|
83905-01-5
|
|
gptkbp:chemicalFormula
|
C38H72N2O12
|
|
gptkbp:contraindication
|
hypersensitivity to macrolides
|
|
gptkbp:developedBy
|
1980
|
|
gptkbp:discoveredBy
|
gptkb:Pliva
|
|
gptkbp:discoveredIn
|
gptkb:Yugoslavia
|
|
gptkbp:eliminationHalfLife
|
68 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
azithromycin
|
|
gptkbp:interactsWith
|
gptkb:cyclosporine
gptkb:warfarin
gptkb:nelfinavir
gptkb:digoxin
antacids
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
1991
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
748.984 g/mol
|
|
gptkbp:origin
|
derived from erythromycin
|
|
gptkbp:patent
|
1981
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:producedBy
|
gptkb:Pfizer
|
|
gptkbp:proteinBinding
|
7–51%
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
allergic reaction
QT prolongation
|
|
gptkbp:usedFor
|
gptkb:sinusitis
gptkb:Mycobacterium_avium_complex
skin infections
sexually transmitted infections
chlamydia
gonorrhea
bacterial infections
otitis media
respiratory tract infections
pharyngitis
community-acquired pneumonia
|
|
gptkbp:bfsParent
|
gptkb:Chlamydia
gptkb:Gonorrhea
gptkb:Erythromycin
gptkb:Macrolides
|
|
gptkbp:bfsLayer
|
5
|